Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer
Milan Radovich(Indiana University Health), Kathy D. Miller(Indiana University Health)
Cited by 29
Related Papers
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer
|Breast Cancer Research|2018|69
A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas
|British Journal of Cancer|2016|63
Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer
|npj Breast Cancer|2017|59
Change, Change, We've Got Change!
|Computers in libraries: Complete coverage of library information technology|1999|0